organic heterocyclic compound dabigatran etexilate 0 627.31692 627.746 reaxys:15496119 pubmed:22298812 CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1 cas:211915-06-9 pubmed:21542663 dabigatran etexilate patent:WO2012077136 pubmed:22431533 pubmed:22536678 An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{<em>N</em>'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1<em>H</em>-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl <em>N</em>-pyridin-2-yl-β-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism. pubmed:22422743 pubmed:21859976 pubmed:22276081 pubmed:22318514 pubmed:22552763 InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) pubmed:22488474 pubmed:22348256 patent:US2011275824 hmdb:HMDB0015641 ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate kegg.drug:D07144 pubmed:22564134 patent:WO2011061080 pubmed:21748501 pubmed:22252796 pubmed:23476049 patent:WO2012027543 drugcentral:776 pubmed:22669799 pubmed:21881389 pubmed:21429525 CHEBI:70746 KSGXQBZTULBEEQ-UHFFFAOYSA-N pubmed:22995531 pubmed:21265583 chebi_ontology pubmed:22803489 ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate pubmed:22563715 C34H41N7O5 pubmed:22782539 patent:WO2007047608